Business Context and Reporting Period
This Form 8-K is filed by Qualigen Therapeutics, Inc. (QLGN) on September 4, 2025. The report addresses a critical listing status update regarding the company's compliance with Nasdaq Capital Market requirements. The filing details a decision by the Nasdaq Hearings Panel concerning the company's failure to meet stockholders' equity thresholds by a previous deadline.
Key Financial Metrics and Liquidity
- Stockholders' Equity: As of June 30, 2025, the company reported negative stockholders' equity of approximately $1.6 million.
- Recent Financing: On July 28, 2025, the company closed a private placement of Series A-3 Preferred Stock, generating net proceeds of approximately $4.3 million.
- Asset Adjustment: An amendment to a promissory note with Marizyme, Inc. on August 21, 2025, resulted in a positive equity adjustment of more than $600,000.
- Compliance Threshold: Nasdaq Listing Rule 5550(b)(1) requires a minimum stockholders' equity of $2.5 million.
Material Changes and Listing Status
The Nasdaq Hearings Panel determined that the company did not demonstrate compliance with the Equity Rule by the July 28, 2025 deadline. Although the company executed transactions (financing and note amendment) that increased equity above the minimum requirement, the Panel ruled these actions could not be considered for the July 28 deadline.
However, the Panel granted a final exception allowing the company to demonstrate compliance upon the filing of its Form 10-Q for the quarter ending September 30, 2025. This report must be filed no later than November 15, 2025. Failure to demonstrate compliance by this date will result in no additional time being granted, likely leading to delisting.
Additionally, the company has regained compliance with the Periodic Filing Rule (Nasdaq Listing Rule 5250(c)(1)) as it is now current in its SEC reporting obligations.
Outlook, Risks, and Management Commentary
The primary risk identified is the potential delisting from The Nasdaq Stock Market LLC if the company fails to show positive stockholders' equity of at least $2.5 million in its upcoming September 30, 2025, quarterly report. The filing indicates that the recent capital raise and asset adjustments were intended to materially improve the equity position, but the final determination rests on the upcoming 10-Q filing.
Investor Verification Checklist
- Verify the final stockholders' equity figure in the upcoming Form 10-Q for the period ended September 30, 2025.
- Confirm the filing date of the September 30, 2025, 10-Q to ensure it is submitted by the November 15, 2025, deadline.
- Monitor Nasdaq announcements for any further decisions regarding the company's listing status post-November 15, 2025.
- Review the terms of the Series A-3 Preferred Stock to understand potential dilution or liquidation preferences.